Shisi Pharmaceutical Group (02005) issued an announcement. The group has obtained the relevant linezolamide dry mix from the China National Drug Administration...
Zhitong Finance App News, Shisi Pharmaceutical Group (02005) issued an announcement. The group has obtained a drug production registration approval from the China National Drug Administration for linezolid dry suspension (5ml: 100mg), which is a Class 4 chemical drug, and is deemed to have passed the consistency evaluation.
According to the announcement, linezolid dry suspension is an oral suspension type. The group was the first domestic company to obtain approval, and has previously obtained approval for the production of linezolid's raw materials and injections. Linezolid dry suspension can be used in neonatal, pediatric and adult patients, mainly to treat hospital-acquired pneumonia caused by specific microbial sensitive strains, community-acquired pneumonia, skin and skin soft tissue infections, and vancomycin-resistant enterococcal fecal infections.